As a leading global healthcare company, we engage with a variety of stakeholders, including public officials, healthcare professionals, patient organisations and business partners. In all our interactions, our first priority is to live up to our responsibilities and all regulatory requirements.
Our policy on transparency is clear; we will be transparent and accountable for how we operate and the transactions that take place when and where we work. This is a part of Novo Nordisk’s company values expressed in the?Novo Nordisk Way?and?in our Business Ethics Compliance Framework, and?how we earn and retain trust and confidence.
Click on the country links below to see our European affiliate disclosures according to local EFPIA association requirements.
The Act requires companies to be transparent about their actions in
addressing and preventing modern slavery and expects continuous
improvement year on year. The Act requires that companies annually
publish a statement on their external website with a link to a
prominent place on their homepage.
Novo Nordisk is in scope for the Modern Slavery Act 2015 and published its first statement in 2017, covering 2016. A second statement was published in 2018, covering 2017. The third statement covering 2018 was published in connection with the publication of our annual results on 1 February 2019.
Collaborations with physicians, research organisations, healthcare institutions and patient organisations help us understand and identify unmet medical needs, drive innovation and develop new medicines and enhance the quality of health education.
Novo Nordisk meets all compliance requirements for disclosure of our financial relationships related to our collaborations with the medical community, as spelled out by relevant decrees and industry guidelines, as well as local laws, including:
We believe that transparent disclosure of financial relationships with healthcare professionals and institutions with whom we collaborate is very important to maintaining trust-based relationships and earning the public's trust.
The U.S. Securities and
Exchange Commission requires companies whose shares are traded on
U.S. stock exchanges to annually disclose whether the products they
manufacture or contract to manufacture contain conflict minerals
that are necessary to the functionality or production of such
products that were sourced from the DRC or adjoining countries.
The conflict minerals covered by this rule are:
Novo Nordisk utilises a four-step supply chain country-of-origin
We collaborate with patient organisations in an open and transparent manner to ensure respect of their independence and integrity and adherence with?our own ethical standards. Our support is based on written agreements that clearly state the purpose of the support as well as the amount and a description of indirect support and any significant non-financial support.
Visit the?Global Offices?page to locate affiliate or use the quick links below.
Quick links to Novo Nordisk affiliates' websites in European region
Disclosure from Novo Nordisk affiliates in the European region with
FYROM - Macedonia
If unable to locate specific projects, please consult the relevant?Novo Nordisk national affiliate's website.